Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities researchers at Svb Leerink issued their FY2019 EPS estimates for Intercept Pharmaceuticals in a research note issued to investors on Tuesday, December 17th, Zacks Investment Research reports. Svb Leerink analyst P. Sarraf expects that the biopharmaceutical company will earn ($10.22) per share for the year. Svb Leerink also issued estimates for Intercept Pharmaceuticals’ Q4 2019 earnings at ($2.35) EPS, Q1 2020 earnings at ($2.52) EPS, Q2 2020 earnings at ($2.28) EPS, Q3 2020 earnings at ($2.08) EPS, Q4 2020 earnings at ($1.09) EPS, FY2020 earnings at ($7.97) EPS, FY2021 earnings at ($3.46) EPS, FY2022 earnings at $6.11 EPS and FY2023 earnings at $15.58 EPS.
Several other equities analysts have also commented on ICPT. Robert W. Baird reiterated a “buy” rating and set a $227.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Citigroup upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their target price for the company from $106.00 to $85.00 in a research report on Wednesday, September 4th. BidaskClub upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 23rd. Credit Suisse Group reissued an “outperform” rating and set a $141.00 price objective (up from $87.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. Finally, Wedbush reaffirmed a “buy” rating and issued a $257.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $137.29.
ICPT stock traded down $0.26 during mid-day trading on Thursday, hitting $123.84. The company had a trading volume of 5,935 shares, compared to its average volume of 888,949. Intercept Pharmaceuticals has a 12 month low of $56.76 and a 12 month high of $131.87. The firm has a market cap of $4.06 billion, a PE ratio of -11.41 and a beta of 1.45. The stock’s fifty day moving average price is $102.53 and its two-hundred day moving average price is $77.51. The company has a debt-to-equity ratio of 4.02, a quick ratio of 5.49 and a current ratio of 5.49.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($2.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.35) by ($0.24). Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The company had revenue of $61.95 million during the quarter, compared to analyst estimates of $63.89 million. During the same period in the prior year, the firm earned ($2.18) earnings per share. Intercept Pharmaceuticals’s revenue was up 31.8% on a year-over-year basis.
Several hedge funds and other institutional investors have recently modified their holdings of ICPT. Larson Financial Group LLC increased its holdings in shares of Intercept Pharmaceuticals by 2,916.7% during the third quarter. Larson Financial Group LLC now owns 543 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 525 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in Intercept Pharmaceuticals in the 3rd quarter valued at $36,000. First Mercantile Trust Co. bought a new position in Intercept Pharmaceuticals in the 3rd quarter valued at $37,000. Compagnie Lombard Odier SCmA acquired a new position in Intercept Pharmaceuticals in the second quarter worth $80,000. Finally, NumerixS Investment Technologies Inc acquired a new position in Intercept Pharmaceuticals in the second quarter worth $88,000. Institutional investors and hedge funds own 79.22% of the company’s stock.
In related news, EVP Christian Weyer sold 4,373 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $100.00, for a total value of $437,300.00. Following the completion of the sale, the executive vice president now owns 17,509 shares in the company, valued at $1,750,900. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Mark Pruzanski sold 35,437 shares of Intercept Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $100.00, for a total value of $3,543,700.00. Following the sale, the chief executive officer now directly owns 469,165 shares in the company, valued at $46,916,500. The disclosure for this sale can be found here. Insiders sold a total of 55,767 shares of company stock worth $5,335,830 in the last ninety days. Insiders own 5.00% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
